Skip to main content

Insilico Medicine

Category: AI in Healthcare

A clinical-stage generative AI company that utilizes an end-to-end platform to accelerate drug discovery, from target identification and molecular design to clinical trial outcome prediction. Insilico Medicine was founded in 2014. The company is led by Alex Zhavoronkov. Based in Hong Kong, China. Team size: 300-500. Total funding raised: $500M+ (including $293M IPO in Dec 2025). Latest round: IPO. Key investors include Warburg Pincus, Qiming Venture Partners, B Capital Group, Prosperity7 Ventures, Deerfield Management, Pavilion Capital, Temasek.

AMW Analysis

Insilico Medicine is a clinical-stage generative AI company, founded in 2014 and based in Hong Kong, that runs an end-to-end platform spanning target identification, molecular design, and clinical trial outcome prediction for drug discovery. It has raised over $500M to date, backed by investors including Warburg Pincus, Qiming Venture Partners, B Capital Group, Prosperity7 Ventures, Deerfield Management, Pavilion Capital, and Temasek. Its recent news flow centers on a Hong Kong Stock Exchange IPO that raised $293M in December 2025, with shares rising in early trading; the company had disclosed its lead candidate for idiopathic pulmonary fibrosis reaching Phase II trials and reported annual revenue of $85.8 million ahead of the listing. Shortly after the IPO, the company announced an $888 million partnership with Servier for AI-driven oncology drug discovery, structured with upfront cash and milestone-based payments. In January 2026 it launched a Science MMAI gym, using reinforcement learning to train generalist models on biology and chemistry tasks aimed at improving performance against scientific benchmarks. Together, these developments show a progression from private R&D platform to public company with an active partnership and continued platform expansion.

AMW analysis, generated from 4 tracked news signals.

Founded
2014
Headquarters
Hong Kong, China
Team size
300-500
Total funding
$500M+ (including $293M IPO in Dec 2025)

Value proposition

Significantly reduces the time and cost of drug development by using generative AI to identify novel biological targets and design 'drug-like' molecules with optimized properties.

Products and solutions

Pharma.AI (Integrated end-to-end drug discovery platform), PandaOmics (AI-driven target discovery and multi-omics analysis), Chemistry42 (Generative chemistry platform for de novo molecular design), inClinico (Clinical trial design and success probability prediction), Science MMAI Gym (Benchmarking and training environment for scientific LLMs)

Unique value

The first company to advance a drug (ISM001-055) that was both discovered and designed by AI into Phase II clinical trials, proving the real-world efficacy of generative biology and chemistry.

Target customer

Global pharmaceutical companies, biotechnology firms, academic research institutions, and AI model developers.

Industries served

Biotechnology, Pharmaceuticals, Healthcare, Artificial Intelligence, Longevity Science

Technology advantage

Proprietary use of Generative Adversarial Networks (GANs) and Reinforcement Learning (RL) to navigate vast chemical spaces; recently pioneered 'Science MMAI Gym' to bridge the gap between general LLMs and rigorous scientific accuracy.

How they differentiate

End-to-end generative AI platform (Pharma.AI) that integrates target discovery (PandaOmics), de novo molecular design (Chemistry42), and clinical trial prediction (inClinico). It is the first company to advance a drug discovered and designed by AI into Phase II clinical trials.

Main competitors

Exscientia, Recursion Pharmaceuticals, Schrodinger, BenevolentAI

Key partnerships

Sanofi (Multi-target strategic research collaboration), Fosun Pharma (Strategic partnership for co-development of drug candidates), Exelixis (Licensing agreement for USP1 inhibitor), Janssen (Johnson & Johnson) (Multi-target drug discovery collaboration), NVIDIA (Infrastructure and AI research collaboration), Takeda (AI drug discovery collaboration announced July 2026, ~$600M deal value)

Notable customers

Sanofi, Fosun Pharma, Janssen (Johnson & Johnson), Exelixis

Major milestones

Advanced ISM001-055, the first AI-discovered and AI-designed drug, to Phase II clinical trials., Secured a multi-billion dollar strategic research collaboration with Sanofi in 2022., Successfully completed a public listing (IPO) in 2025., Launched 'Science MMAI Gym' in January 2026 to optimize LLMs for scientific research accuracy.

Growth metrics

Estimated $80M - $100M ARR (2025); pipeline of 30+ therapeutic assets with multiple programs in Phase I and Phase II clinical trials.

Market positioning

Clinical-stage leader in Generative AI for drug discovery and longevity science.

Geographic focus

Global (Headquartered in Hong Kong and New York, with major R&D centers in Abu Dhabi, Montreal, and Shanghai).

Patents and IP

Extensive global portfolio including patents for AI-designed small molecules (e.g., USP1 inhibitors, QPCTL inhibitors) and proprietary algorithms within the Pharma.AI software suite.

About Alex Zhavoronkov

Alex Zhavoronkov, Ph.D., is a pioneer in the application of generative AI for drug discovery and aging research. He founded Insilico Medicine in 2014 and has led the company to become a global leader in clinical-stage AI-driven drug development. He previously founded Deep Longevity (acquired by Endurance Longevity) and has published over 150 peer-reviewed papers. He holds a PhD in Biophysics from Moscow State University and an MS in Biotechnology from Johns Hopkins University.

Latest news about Insilico Medicine

More AI in Healthcare companies

Official website: